Clinical trial · Observational
The Use of Angiotensin Receptor Blockers and the Risk of Cancer
NCT02215733CI-TRIAL-00015371completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective of this study was to assess whether angiotensin blockers (ARBs) and telmisartan in particular, are associated with an increased overall risk of the four most common cancers, namely, lung, colorectal, breast and prostate cancers. A secondary objective was to explore these effects separately for each of the four cancers and in combination with angiotensin-converting-enzyme-inhibitors (ACEIs).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasm | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ACEI | Drug | — | UNRESOLVED |
| ARB | Drug | — | UNRESOLVED |
| Beta-blockers | Drug | — | UNRESOLVED |
| Diuretics | Drug | — | UNRESOLVED |
| Telmisartan | Drug | Telmisartan | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Patients prescribed antihypertensives
- interventionNames
- Drug: ARB
- Drug: ACEI
- Drug: Beta-blockers
- Drug: Diuretics
- Drug: Telmisartan
Primary outcomes (5)
- measure
- Number of patients with occurrences of lung, colorectal, breast and prostate cancers related to use of ARBs
- timeFrame
- 16 years
- measure
- Determination of dose-response in terms of ARB duration of use and cumulative dose and the risk of lung, colorectal, breast and prostate cancers combined
- timeFrame
- 16 years
- measure
- Ratio of occurrence of lung, colorectal, breast and prostate cancers related to use of ARBs, relative to beta-blockers and diuretics
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients prescribed an antihypertensive agent between 01-JAN-1995 and 31-DEC-2008 with at least two years of up-to-standard medical history in United Kingdom's General Practice Research Database (GPRD) Exclusion Criteria: * History of cancer at any time prior to cohort entry
References
Publications (0)
Data not yet available
No reference posted for this study.